{"id":451667,"date":"2021-03-05T08:03:31","date_gmt":"2021-03-05T13:03:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451667"},"modified":"2021-03-05T08:03:31","modified_gmt":"2021-03-05T13:03:31","slug":"immutep-expands-part-b-of-tacti-002-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-expands-part-b-of-tacti-002-study\/","title":{"rendered":"Immutep Expands Part B of TACTI-002 Study"},"content":{"rendered":"

\nFollows positive efficacy and safety review
\n<\/h2>\n
\n

Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) — \u2013 Immutep Limited <\/b>(ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has decided to expand Part B of its TACTI-002 Phase II trial, under the study\u2019s Simon\u2019s two- stage clinical trial design. Immutep has commenced recruitment of an additional 13 second line Non-Small Cell Lung Cancer (NSCLC) patients, forming Stage 2 of Part B.<\/p>\n

The decision follows a preliminary safety and efficacy review by the Data Monitoring Committee and its recommendation, based on the patients recruited in Stage 1 of Part B.<\/p>\n

\n About the TACTI-002 Trial<\/b>\n <\/p>\n

TACTI-002 (Two ACTive Immunotherapies) is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as \u201cMSD\u201d outside the United States and Canada). The study is evaluating the combination of efti with MSD\u2019s KEYTRUDA\u00ae (pembrolizumab) in patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.<\/p>\n

The trial is a Phase II, Simon\u2019s two-stage, non-comparative, open-label, single-arm, multicentre clinical study that is taking place in up to 12 study centres across Australia, Europe, the UK and US.<\/p>\n

Patients participating in three parts:<\/p>\n